MRIdian Featured in Nearly 40 Abstracts at ESTRO 2022

By News Release


ViewRay, Inc. announces that its MRI-guided radiation therapy system, MRIdian, is included in nearly 40 presentations and posters at the 2022 ESTRO meeting in Copenhagen, Denmark.

MRIdian-focused presentations and posters, submitted by MRIdian clinical teams from across the globe and accepted as part of ESTRO's Scientific Sessions, highlight MRIdian's clinical value treating a wide variety of cancers including pancreatic, prostate, liver, rectal, cervical and central/ultracentral lung tumors. Additional topics highlighted include patient satisfaction, cost/benefit analysis, and single day MRIdian treatments.

MRIdian A3i, currently available only in the US, is ViewRay's 4th generation of real-time tissue tracking with automatic beam gating, now coupled with new treatment delivery capabilities focused on enhancing on-table adaptive workflow efficiency and expanding clinical utility. 

This month marks 10 years since ViewRay introduced real-time tissue tracking with automatic beam gating. To date, MRIdian customers have treated more than 21,000 patients utilizing this feature on over 200,000 fractions. MRIdian remains the first and only system to offer real-time tissue tracking with automatic beam gating.

Over 21,000 patients have been treated with MRIdian. Currently, 50 MRIdian systems are installed at hospitals around the world where they are used to treat a wide variety of solid tumors and are the focus of numerous ongoing research efforts.